The mission of the Critical Path for Alzheimer's Disease (CPAD) consortium is to accelerate the Alzheimer's disease (AD) drug development process, for the benefit of people living with AD. As a US-based, public-private partnership, CPAD works with industry, regulators, researchers and patient organisations on various fronts, one of which involves the creation of integrated databases for cohort and clinical trial data.
On 12 April, CPAD announced the expansion of its AD patient-level data repository, which now incorporates over 21,000 patient-level records from 42 cohort studies and clinical trials. These data, which have been contributed by pharmaceutical industry partners and are safely stored in the CPAD repository, can now be accessed by scientific researchers. De-identified datasets include patient-level information on biomarkers, genotype, cognitive and functional assessments and demographics, representing a valuable resource for the generation of new drug development tools and disease progression models. Klaus Romero, Chief Scientific Officer of the Critical Path Institute, highlighted the importance of data sharing for AD research, stating "CPAD provides the AD field with a unique opportunity to transform patient-level data into actionable solutions, which can in turn transform the drug development process for AD."
https://c-path.org/c-paths-alzheimers-disease-consortium-expands-data-repository/